Product Description
Mechanisms of Action: CAR-T
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: He Huang
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for RD13-01](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Hematological Unspecified|Oncology Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BHCT-RD13-01-03 | N/A |
Unknown status |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|T-Cell Leukemia |
2021-11-15 |
|
BHCT-RD13-01-02 | P1 |
Completed |
Oncology Hematological Unspecified|Oncology Unspecified |
2021-02-17 |